
High-Quality RAD 140 for Sale – Tested & Proven
RAD 140 is a type of SARM, a compound designed to target androgen receptors in the body. These receptors are found in muscles and bones, and when activated, they can help build muscle and improve strength. Unlike traditional steroids, RAD 140 is selective, meaning it focuses on specific tissues and aims to reduce unwanted side effects. It's mainly used for research purposes, as it's not approved for human consumption.
Researchers are interested in RAD 140 because it shows promise in areas like muscle growth, fat loss, and even neuroprotection. Studies have explored its effects on animals, showing it can increase muscle mass and protect brain cells from damage. For example, one study found RAD 140 reduced cell death in rat neurons, which could have implications for diseases like Alzheimer's.
When looking for RAD 140 for sale, quality is critical. Not all suppliers offer pure or safe products. Low-quality RAD 140 might not work as intended or could contain harmful impurities. High-quality RAD 140 should be: Third-Party Tested : This means an independent lab checks the product for purity and strength. Reputable suppliers like PureRawz provide Certificates of Analysis (CoA) to prove their products are clean and effective.
: This means an independent lab checks the product for purity and strength. Reputable suppliers like PureRawz provide Certificates of Analysis (CoA) to prove their products are clean and effective. Pure : The product should be at least 98% pure to ensure it delivers the desired effects without contaminants.
: The product should be at least 98% pure to ensure it delivers the desired effects without contaminants. Well-Packaged : Good packaging keeps the product safe and shows the supplier cares about quality. PureRawz, for instance, uses clean, sealed packaging with clear labeling.
: Good packaging keeps the product safe and shows the supplier cares about quality. PureRawz, for instance, uses clean, sealed packaging with clear labeling. Backed by Reputation: Suppliers with a strong track record, like PureRawz, are trusted because they respond to customer questions and maintain high standards.
Choosing a trusted supplier ensures you're getting a product that's safe for research and meets high standards.
RAD 140 has caught attention for its potential benefits in research. Here's what studies and user experiences suggest:
RAD 140 is known for helping build lean muscle. In animal studies, it increased body weight in young primates, showing strong anabolic effects. This makes it a popular choice for researchers studying muscle hypertrophy. Many users report noticeable muscle gains after a few weeks, especially when combined with exercise. One user shared that after nine weeks of RAD 140 at 20-30 mg daily, they saw enhanced lean muscle growth with a 'dry, grainy look.'
Researchers have found RAD 140 can boost strength and stamina. In one case, a 64-year-old man reported cutting his bike commute time from 60 minutes to under 25 minutes after using RAD 140 for two months. This suggests it could help improve physical performance in research settings.
RAD 140 may help burn fat while preserving muscle. Its ability to increase muscle mass can raise metabolism, which supports fat loss. This makes it appealing for studies on body composition.
Beyond muscle, RAD 140 shows promise in protecting brain cells. In rat studies, it reduced cell death caused by harmful substances, suggesting potential benefits for brain health research.
Compared to steroids, RAD 140 is designed to have fewer side effects. It targets muscles and bones without affecting other tissues, like the prostate. However, researchers must still follow safety guidelines, as long-term effects are not fully studied.
Quality testing is a big deal when buying RAD 140. Reputable suppliers like PureRawz use third-party labs to verify their products. Here's how it works: Purity Testing : Labs check that the RAD 140 is at least 98% pure. This ensures it's free from harmful fillers or contaminants.
: Labs check that the RAD 140 is at least 98% pure. This ensures it's free from harmful fillers or contaminants. Certificates of Analysis (CoA) : These documents show the exact composition of the product. Pure Rawz provides CoAs for transparency, so researchers know what they're getting.
: These documents show the exact composition of the product. Pure Rawz provides CoAs for transparency, so researchers know what they're getting. Consistency: Each batch is tested to ensure it meets the same high standards every time.
When buying RAD 140, always ask for proof of third-party testing. Suppliers like PureRawz make this easy by sharing lab reports on their website.
PureRawz is a well-known name in the SARMs community, and for good reason. Here's why researchers choose them: Third-Party Testing : Every product, including RAD 140, is tested by independent labs. This builds trust and ensures quality.
: Every product, including RAD 140, is tested by independent labs. This builds trust and ensures quality. Fast Shipping : Orders are fulfilled from the USA, so shipping is quick and reliable. Many users report receiving their orders in 3-15 days.
: Orders are fulfilled from the USA, so shipping is quick and reliable. Many users report receiving their orders in 3-15 days. Wide Selection : PureRawz offers RAD 140 in various forms, like liquid, capsules, or stacks with other compounds like YK-11 or MK-677. This gives researchers flexibility.
: PureRawz offers RAD 140 in various forms, like liquid, capsules, or stacks with other compounds like YK-11 or MK-677. This gives researchers flexibility. Customer Support : They're known for quick responses to questions, which is helpful for researchers with specific needs.
: They're known for quick responses to questions, which is helpful for researchers with specific needs. Discounts: PureRawz often provides discount codes, like CAPRED25 for 15% off, making it more affordable to buy high-quality RAD 140.
However, some users have reported slow shipping times, with delays up to 3.5 weeks. Despite this, the consensus is that PureRawz delivers legitimate, high-quality products.
RAD 140 is typically studied in doses of 10-20 mg per day, though this can vary based on the research goals. Here are some tips for safe research: Start Low : Begin with a smaller dose, like 10 mg, to see how it affects the study subject.
: Begin with a smaller dose, like 10 mg, to see how it affects the study subject. Cycle Properly : Researchers often use RAD 140 for 8-12 weeks, followed by a break to avoid potential tolerance buildup.
: Researchers often use RAD 140 for 8-12 weeks, followed by a break to avoid potential tolerance buildup. Post-Cycle Therapy (PCT) : Some studies include PCT compounds, like Arimistane, to balance hormones after a cycle. PureRawz offers PCT products for this purpose.
: Some studies include PCT compounds, like Arimistane, to balance hormones after a cycle. PureRawz offers PCT products for this purpose. Follow Guidelines: RAD 140 is for research only, not human consumption. Always follow local regulations and consult an Institutional Review Board (IRB) for clinical studies.
When buying RAD 140, stick to trusted suppliers. PureRawz is a top choice due to its focus on quality and transparency. Other options include: Paradigm Peptides : Known for fast delivery and positive user reviews. One user reported great results with no side effects after using their RAD 140.
: Known for fast delivery and positive user reviews. One user reported great results with no side effects after using their RAD 140. BehemothLabz : Offers lab-synthesized RAD 140 with third-party testing and fast shipping.
: Offers lab-synthesized RAD 140 with third-party testing and fast shipping. Sports Technology Labs : Sells liquid RAD 140 with 98%+ purity, bottled in the USA.
: Sells liquid RAD 140 with 98%+ purity, bottled in the USA. Chemyo: Praised for affordable powder options, though you'll need a precision scale for accurate dosing.
Always check for third-party testing and read user reviews before buying. Avoid suppliers with poor customer service or no lab reports, as some Reddit users have warned about inconsistent experiences with certain vendors.
While RAD 140 is promising, there are risks to consider: Not for Human Use : RAD 140 is sold for research only. It's not approved by the FDA or allowed by organizations like WADA.
: RAD 140 is sold for research only. It's not approved by the FDA or allowed by organizations like WADA. Potential Side Effects : Though designed to minimize side effects, some researchers note temporary issues like fatigue or hormonal changes. Always monitor study subjects closely.
: Though designed to minimize side effects, some researchers note temporary issues like fatigue or hormonal changes. Always monitor study subjects closely. Supplier Reliability : Some suppliers, including PureRawz, have faced complaints about slow shipping. Double-check stock availability before ordering.
: Some suppliers, including PureRawz, have faced complaints about slow shipping. Double-check stock availability before ordering. Legal Issues: Ensure your research complies with local laws, as SARMs are regulated in many areas.
Finding high-quality RAD 140 for Sale is easier when you choose a trusted supplier like PureRawz. With third-party testing, fast shipping, and a strong reputation, they're a go-to for researchers studying muscle growth, strength, and neuroprotection. RAD 140 offers exciting potential, but quality matters. Always verify purity, read user reviews, and follow research guidelines to ensure safe and effective studies. Whether you're exploring RAD 140 alone or in stacks, suppliers like PureRawz make it simple to get tested, proven products for your research needs.
TIME BUSINESS NEWS

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 hours ago
- Yahoo
New Study Using Aptar's Nasal Drug Delivery System Validates Insulin Nasal Spray to Deliver Alzheimer's Drug Directly to the Brain
Research by Wake Forest University School of Medicine provides a crucial method for future Alzheimer's disease treatment trials and reveals key differences in how the drug is absorbed in people with early cognitive decline CRYSTAL LAKE, Ill., July 23, 2025--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that its nasal drug delivery system was used in a recently published brain imaging study from Wake Forest University School of Medicine. According to the university's press release, the "groundbreaking" study confirms a vital step toward new Alzheimer's treatments: intranasal insulin, delivered via nasal spray, safely and effectively reaches key memory regions of the brain in older adults. The study also revealed that people with early cognitive decline may absorb it differently. This research, published in Alzheimer's & Dementia: Translational Research & Clinical Interventions, describes the results of a milestone positron emission tomography (PET) imaging study. According to the Wake Forest team, the results directly show that intranasal insulin travels to 11 key brain regions associated with memory and cognition. Previously, researchers faced challenges in earlier intranasal insulin trials because they could not confirm if the treatment was reaching its brain targets. The imaging protocol used a precision nasal delivery system supplied by Aptar Pharma, and could be adapted for other intranasal therapies targeting neurological disorders. "The results of the study represent a significant step forward in medicine as they validate that our nasal delivery system was effective in delivering intranasal insulin safely and effectively to specific regions of the brain," said Reenal Gandhi, Aptar Pharma's Director of Business Development. "Aptar has over 30 years of experience in nasal drug delivery system, including in the area of neurodegenerative diseases, and the patient is at the center of everything we design. While we have nasally delivered medications in emergency and routine care, we believe that the nasal route holds potential for more developments. As scientific understanding and development advance, we see continued opportunities for intranasal delivery to improve how therapeutics are delivered to the central nervous system." "This study fills a critical gap in our understanding of how intranasal insulin reaches the brain," said Suzanne Craft, Ph.D., professor of gerontology and geriatric medicine at Wake Forest University School of Medicine and director of the Wake Forest Alzheimer's Disease Research Center. "We needed direct evidence that the drug is able to reach key brain targets. An unexpected finding was the observation that uptake may differ in people with early cognitive decline. This means we now have a roadmap directly to the brain." The Wake Forest study involved 16 older adults (average age 72), including seven who were cognitively normal and nine with mild cognitive impairment (MCI). Using a novel radiotracer, [68Ga]Ga-NOTA-insulin, delivered with a specialized six-spray nasal system, participants underwent a 40-minute brain PET scan followed by whole-body imaging. Participants described the nasal spray as "surprisingly easy." The researchers found: Elevated insulin uptake in critical memory and cognition areas, including the hippocampus, olfactory cortex, amygdala and temporal lobe. Cognitively normal individuals showed higher uptake and distinct timing patterns of insulin delivery compared to those with MCI, who exhibited rapid initial uptake followed by quicker clearance. In women, insulin uptake correlated strongly with factors linked to healthy cardiovascular function and elevated ptau217 levels (a marker of brain amyloid, the sticky protein that accumulates in the brain in Alzheimer's disease) were associated with decreased brain absorption across multiple regions. Only two participants reported mild headaches post-scan, which resolved within 24 hours, indicating the procedure was well-tolerated. "One of the biggest challenges in developing treatments for brain diseases is getting agents into the brain," Craft said. "This study shows we can validate intranasal delivery systems effectively, an essential step before launching therapeutic trials." Given recent concerns around the limited efficacy and side-effect profiles of some anti-amyloid drugs, this validation strategy supports a broader approach to Alzheimer's treatment, including metabolic and delivery-focused interventions. The findings could help explain why some patients respond better to intranasal insulin therapy than others, potentially leading to personalized treatment approaches. "There's an urgent need to identify effective and feasible ways to prevent and treat Alzheimer's dementia," said Craft. "These findings show that we can now validate whether treatments are actually reaching their intended brain targets, which is critical information for designing successful trials." The Wake Forest team is now planning larger validation studies within the next 12-18 months to explore how vascular health, amyloid accumulation and sex differences influence brain insulin delivery. "While there's still a lot to learn, these findings show that we now have the tools to validate intranasal drug delivery to the brain," Craft said. "This is promising news for developing more effective and accessible treatments for Alzheimer's disease." Aptar offers a full range of Orally Inhaled and Nasal Drug Product (OINDP) systems and services to support this growing sector. Aptar offers advanced intranasal drug delivery services, including everything from manufacturing, formulation development all the way through to clinical and commercial product manufacturing. Aptar's nasal spray systems are designed to reliably deliver precise nasal drug dosing in an easy to use, safe, and portable package for both systemic and local administration with rapid onset capabilities. About Aptar Aptar is a global leader in drug and consumer product dosing, dispensing and protection technologies. Aptar serves a number of attractive end markets including pharmaceutical, beauty, food, beverage, personal care and home care. Using market expertise, proprietary design, engineering and science to create innovative solutions for many of the world's leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. Aptar is headquartered in Crystal Lake, Illinois and has over 13,000 dedicated employees in 20 countries. For more information, visit This press release contains forward-looking statements, including the potential outcomes of the nasal delivery system for intranasal insulin. Forward-looking statements generally can be identified by the fact that they do not relate strictly to historical or current facts and by use of words such as "expects," "anticipates," "believes," "estimates," "future," "potential," "continues" and other similar expressions or future or conditional verbs such as "will," "should," "would" and "could" are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results or other events may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to: the successful integration of acquisitions; the regulatory environment; and competition, including technological advances. For additional information on these and other risks and uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Form 10-K and Forms 10-Q. We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as otherwise required by law. View source version on Contacts Investor Relations Contact: Mary 815-479-5658 Media Contact: Katie 815-479-5671


Business Wire
19 hours ago
- Business Wire
New Study Using Aptar's Nasal Drug Delivery System Validates Insulin Nasal Spray to Deliver Alzheimer's Drug Directly to the Brain
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that its nasal drug delivery system was used in a recently published brain imaging study from Wake Forest University School of Medicine. According to the university's press release, the 'groundbreaking' study confirms a vital step toward new Alzheimer's treatments: intranasal insulin, delivered via nasal spray, safely and effectively reaches key memory regions of the brain in older adults. The study also revealed that people with early cognitive decline may absorb it differently. This research, published in Alzheimer's & Dementia: Translational Research & Clinical Interventions, describes the results of a milestone positron emission tomography (PET) imaging study. According to the Wake Forest team, the results directly show that intranasal insulin travels to 11 key brain regions associated with memory and cognition. Previously, researchers faced challenges in earlier intranasal insulin trials because they could not confirm if the treatment was reaching its brain targets. The imaging protocol used a precision nasal delivery system supplied by Aptar Pharma, and could be adapted for other intranasal therapies targeting neurological disorders. 'The results of the study represent a significant step forward in medicine as they validate that our nasal delivery system was effective in delivering intranasal insulin safely and effectively to specific regions of the brain,' said Reenal Gandhi, Aptar Pharma's Director of Business Development. 'Aptar has over 30 years of experience in nasal drug delivery system, including in the area of neurodegenerative diseases, and the patient is at the center of everything we design. While we have nasally delivered medications in emergency and routine care, we believe that the nasal route holds potential for more developments. As scientific understanding and development advance, we see continued opportunities for intranasal delivery to improve how therapeutics are delivered to the central nervous system.' 'This study fills a critical gap in our understanding of how intranasal insulin reaches the brain,' said Suzanne Craft, Ph.D., professor of gerontology and geriatric medicine at Wake Forest University School of Medicine and director of the Wake Forest Alzheimer's Disease Research Center. 'We needed direct evidence that the drug is able to reach key brain targets. An unexpected finding was the observation that uptake may differ in people with early cognitive decline. This means we now have a roadmap directly to the brain.' The Wake Forest study involved 16 older adults (average age 72), including seven who were cognitively normal and nine with mild cognitive impairment (MCI). Using a novel radiotracer, [68Ga]Ga-NOTA-insulin, delivered with a specialized six-spray nasal system, participants underwent a 40-minute brain PET scan followed by whole-body imaging. Participants described the nasal spray as 'surprisingly easy.' The researchers found: Elevated insulin uptake in critical memory and cognition areas, including the hippocampus, olfactory cortex, amygdala and temporal lobe. Cognitively normal individuals showed higher uptake and distinct timing patterns of insulin delivery compared to those with MCI, who exhibited rapid initial uptake followed by quicker clearance. In women, insulin uptake correlated strongly with factors linked to healthy cardiovascular function and elevated ptau217 levels (a marker of brain amyloid, the sticky protein that accumulates in the brain in Alzheimer's disease) were associated with decreased brain absorption across multiple regions. Only two participants reported mild headaches post-scan, which resolved within 24 hours, indicating the procedure was well-tolerated. 'One of the biggest challenges in developing treatments for brain diseases is getting agents into the brain,' Craft said. 'This study shows we can validate intranasal delivery systems effectively, an essential step before launching therapeutic trials.' Given recent concerns around the limited efficacy and side-effect profiles of some anti-amyloid drugs, this validation strategy supports a broader approach to Alzheimer's treatment, including metabolic and delivery-focused interventions. The findings could help explain why some patients respond better to intranasal insulin therapy than others, potentially leading to personalized treatment approaches. 'There's an urgent need to identify effective and feasible ways to prevent and treat Alzheimer's dementia,' said Craft. 'These findings show that we can now validate whether treatments are actually reaching their intended brain targets, which is critical information for designing successful trials.' The Wake Forest team is now planning larger validation studies within the next 12-18 months to explore how vascular health, amyloid accumulation and sex differences influence brain insulin delivery. 'While there's still a lot to learn, these findings show that we now have the tools to validate intranasal drug delivery to the brain,' Craft said. 'This is promising news for developing more effective and accessible treatments for Alzheimer's disease.' Aptar offers a full range of Orally Inhaled and Nasal Drug Product (OINDP) systems and services to support this growing sector. Aptar offers advanced intranasal drug delivery services, including everything from manufacturing, formulation development all the way through to clinical and commercial product manufacturing. Aptar's nasal spray systems are designed to reliably deliver precise nasal drug dosing in an easy to use, safe, and portable package for both systemic and local administration with rapid onset capabilities. About Aptar Aptar is a global leader in drug and consumer product dosing, dispensing and protection technologies. Aptar serves a number of attractive end markets including pharmaceutical, beauty, food, beverage, personal care and home care. Using market expertise, proprietary design, engineering and science to create innovative solutions for many of the world's leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. Aptar is headquartered in Crystal Lake, Illinois and has over 13,000 dedicated employees in 20 countries. For more information, visit This press release contains forward-looking statements, including the potential outcomes of the nasal delivery system for intranasal insulin. Forward-looking statements generally can be identified by the fact that they do not relate strictly to historical or current facts and by use of words such as 'expects,' 'anticipates,' 'believes,' 'estimates,' 'future,' 'potential,' 'continues' and other similar expressions or future or conditional verbs such as 'will,' 'should,' 'would' and 'could' are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results or other events may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to: the successful integration of acquisitions; the regulatory environment; and competition, including technological advances. For additional information on these and other risks and uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' in our Form 10-K and Forms 10-Q. We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as otherwise required by law.


Business Insider
a day ago
- Business Insider
Bitget Lists Alliance Games (COA) for Spot Trading
Seychelles, Victoria, July 23rd, 2025, Chainwire Bitget, the leading cryptocurrency exchange and Web3 company, has announced the listing of Alliance Games (COA) in the Innovation and GameFi Zone, adding it for spot trading. Trading for the COA/USDT pair will begin on 23 July 2025, 10:00 (UTC), with withdrawals available from 24 July 2025, 11:00 (UTC). Alliance Games is a decentralized Web3 gaming infrastructure platform that blends AI-powered game creation, blockchain-based multiplayer networking, and distributed hosting to transform how games are developed, deployed, and monetized. $COA, fuels the ecosystem, granting developers access to infrastructure, rewarding node operators, and enabling users to stake, govern and unlock premium features. Built to be chain-agnostic, Alliance Games supports multiple blockchains, making it a versatile foundation for the next generation of Web3 gaming titles. Designed for both developers and players, Alliance Games emphasizes community ownership and seamless integration of blockchain technology into gaming. Its decentralized server and data infrastructure offer a more secure, scalable, and censorship-resistant alternative to traditional models. With AI-driven tools, the platform lowers the barrier to game creation, encouraging creativity and faster development cycles. Its flagship title, Chain of Alliance, a turn-based RPG, showcases the full potential of the platform, demonstrating how Web3 principles like user ownership and transparent economies can redefine the gaming experience. Bitget continues to expand its offerings, positioning itself as a leading platform for cryptocurrency trading. The exchange has established a reputation for innovative solutions that empower users to explore crypto within a secure CeDeFi ecosystem. With an extensive selection of over 800 cryptocurrency pairs and a commitment to broaden its offerings to more than 900 trading pairs, Bitget connects users to various ecosystems, including Bitcoin, Ethereum, Solana, Base, and TON. The addition of Alliance Games into Bitget's portfolio marks a significant step toward expanding its ecosystem by embracing decentralized gaming infrastructure, supporting AI-driven innovation, and empowering community-led development in the Web3 gaming space. For more details on Alliance Games, visit here. About Bitget Established in 2018, Bitget is the world's leading cryptocurrency exchange and Web3 company. Serving over 120 million users in 150+ countries and regions, the Bitget exchange is committed to helping users trade smarter with its pioneering copy trading feature and other trading solutions, while offering real-time access to Bitcoin price, Ethereum price, and other cryptocurrency prices. Formerly known as BitKeep, Bitget Wallet is a leading non-custodial crypto wallet supporting 130+ blockchains and millions of tokens. It offers multi-chain trading, staking, payments, and direct access to 20,000+ DApps, with advanced swaps and market insights built into a single platform. Bitget is driving crypto adoption through strategic partnerships, such as its role as the Official Crypto Partner of the World's Top Football League, LALIGA, in EASTERN, SEA and LATAM markets, as well as a global partner of Turkish National athletes Buse Tosun Çavuşoğlu (Wrestling world champion), Samet Gümüş (Boxing gold medalist) and İlkin Aydın (Volleyball national team), to inspire the global community to embrace the future of cryptocurrency. Aligned with its global impact strategy, Bitget has joined hands with UNICEF to support blockchain education for 1.1 million people by 2027. In the world of motorsports, Bitget is the exclusive cryptocurrency exchange partner of MotoGP, one of the world's most thrilling championships. For more information, visit: Website | Twitter | Telegram | LinkedIn | Discord | Bitget Wallet For media inquiries, please contact: media@ Risk Warning: Digital asset prices are subject to fluctuation and may experience significant volatility. Investors are advised to only allocate funds they can afford to lose. The value of any investment may be impacted, and there is a possibility that financial objectives may not be met, nor the principal investment recovered. Independent financial advice should always be sought, and personal financial experience and standing carefully considered. Past performance is not a reliable indicator of future results. Bitget accepts no liability for any potential losses incurred. Nothing contained herein should be construed as financial advice. For further information, please refer to our Terms of Use.